Drug Trial Radar · NCT03702361
Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
Last checked: Nov 19, 2026Latest source record: Mar 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Sep 4, 2018
Primary completion
Sep 30, 2019
Study completion Mar 18, 2021
Sponsor
- Lead sponsor
- Shaare Zedek Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
During the past two years, the investigator has performed succsefully an IIR wherein patients with GD, previously treated with velaglucerase alfa ERT were gradually switched to a 10 minutes (rapid) administration of the same ERT. The success was expressed as safety (no clinically meaningful AEs, no antibodies detected, home therapy), efficacy ("lack of deterioration") and patients' satisfaction. The latter was based not just on specific questionnaires and analog scales, but particularly by the patients' sharing the experience with other patients and consequently repeated requests by many to switch to a rapid administration of their ERT. Therefore, the investigator is hereby proposing to investigate the safety and efficacy of a 10 minutes administration of velaglucerase alfa in a cohort of treatment-naive patients. The current VPRIV label is restricted to a dosage of 60 units/kg body weight every other week (60 units/kg EOW) - this dose will be used throughout the study period. The enzyme will be provided by Shire, which will also provide a research grant for the conduction of the trial.
Conditions
- Primary Disease
Interventions
VPRIVDrug
VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in spleen volume measured by MRITime frame: 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Michal Becker- Cohen
Jerusalem, Please Select..., Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.